Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

AMPHOTEC 50 MG DIN 02241750

Status: Cancelled Post Market
Holder: THREE RIVERS PHARMACEUTICALS LLC
Molecule: AMPHOTERICIN B

Health Canada record

Active ingredient(s)AMPHOTERICIN B 50 MG
Dosage formPowder For Suspension
RouteIntravenous
SchedulePRESCRIPTION
ClassHuman
ATCJ02AA01 AMPHOTERICIN B
Original market date26-Feb-2007
Current status date22-Aug-2013
SourceHealth Canada DPD

No Canadian shortage report is currently matched to this DIN.

Other Canadian products containing AMPHOTERICIN B

DINProductCompanyFormStrengthStatus
02241630AMBISOMEASTELLAS PHARMA CANADA INCPowder For SolutionAMPHOTERICIN B 50 MGMarketed
02405032AMPHOTERICIN B FOR INJECTION, USPSTERIMAX INCPowder For SolutionAMPHOTERICIN B 50 MGApproved
00029149FUNGIZONECHEPLAPHARM ARZNEIMITTEL GMBHPowder For SolutionAMPHOTERICIN B 50 MGMarketed
02554186TARO-AMPHOTERICIN B LIPOSOMALTARO PHARMACEUTICALS INCPowder For SolutionAMPHOTERICIN B 50 MGApproved
02231590ABELCETLEADIANT BIOSCIENCES, INCSuspensionAMPHOTERICIN B 5 MGCancelled Post Market
02241749AMPHOTEC 100 MGTHREE RIVERS PHARMACEUTICALS LLCPowder For SuspensionAMPHOTERICIN B 100 MGCancelled Post Market

Notices of Compliance

NOCDateSubmissionReason
77042006-01-26New Drug Submission (NDS)MANUFACTURER NAME CHANGE
762003-06-11New Drug Submission (NDS)MANUFACTURER NAME CHANGE
9632000-04-26New Drug Submission (NDS)

International API supply for AMPHOTERICIN B

3 valid EDQM Certificates of Suitability from 3 holders. 6 active FDA Drug Master Files.

Request a quote for AMPHOTEC 50 MG

How to read a Canadian DIN record